Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) is anticipated to release its earnings data on Thursday, February 6th. Analysts expect Rapport Therapeutics to post earnings of ($0.62) per share for the quarter.
Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.07. On average, analysts expect Rapport Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Rapport Therapeutics Price Performance
Shares of Rapport Therapeutics stock opened at $17.77 on Wednesday. Rapport Therapeutics has a fifty-two week low of $12.09 and a fifty-two week high of $29.74. The business’s fifty day moving average is $17.67 and its two-hundred day moving average is $20.40.
Rapport Therapeutics Company Profile
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Stories
- Five stocks we like better than Rapport Therapeutics
- Options Trading – Understanding Strike Price
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- Most Volatile Stocks, What Investors Need to Know
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- What is Put Option Volume?
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
